GlassScriptPhysician profile
Roberta S Hahn
NPI 1770936866
$6,980.20
in general payments reported to CMS, 2019-2025
27 companies · $1,692 in 2025
The $1,692 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $781 · 2022: $1,045 · 2023: $1,188 · 2024: $2,274 · 2025: $1,692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,842 · Education: $312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,842.19 |
| Education | $311.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $947.08 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $940.08 | 2021-2025 | Otezla, Repatha, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $605.10 | 2024-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $593.73 | 2022-2025 | Airsupra, Farxiga, Fasenra |
| Astellas Pharma US INC | $572.41 | 2021-2025 | Veozah |
| Novo Nordisk INC | $552.62 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $466.07 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Axsome Therapeutics, INC. | $462.14 | 2023-2025 | Auvelity |
| Abbvie INC. | $381.51 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $305.31 | 2024-2025 | Spravato |
| Paratek Pharmaceuticals, INC. | $182.74 | 2022-2025 | Nuzyra |
| Otsuka America Pharmaceutical, INC. | $104.64 | 2023-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $102.59 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $101.11 | 2021-2024 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $79.69 | 2024-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $74.30 | 2022-2025 | |
| Exact Sciences Corporation | $73.71 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.74 | 2022-2025 | Jardiance |
| Lundbeck LLC | $66.98 | 2022-2024 | Rexulti |
| Pfizer INC. | $63.67 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $61.24 | 2024-2025 | Austedo Xr, Austedo Xr |
| Baxter Healthcare | $42.36 | 2024-2025 | Hillrom - Cardiac Ambulatory Monitor |
| Abbott Laboratories | $41.42 | 2024-2025 | Freestyle Libre 3 |
| Supernus Pharmaceuticals, INC. | $39.47 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $21.25 | 2021 | |
| Corcept Therapeutics | $15.54 | 2025 | Korlym |
| Dexcom, INC. | $13.70 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberta Hahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.